Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: A systematic review and meta-analysis

Oncologist

Volumn 18, Issue 12, 2013, Pages 1248-1255

  Yin, Ming ^a   Zhou, Jie ^a   Gorak, Edward J ^b   Quddus, Fahd ^b  

^a Department of Internal Medicine ^*  (United States)

^b GEISINGER MEDICAL CENTER   (United States)

Author keywords

Cancer; Diabetes; Meta analysis; Metformin; Survival

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; INSULIN; METFORMIN; SULFONYLUREA;

ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; DEATH; DISEASE ASSOCIATION; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

CANCER; DIABETES; META-ANALYSIS; METFORMIN; SURVIVAL;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; NEOPLASMS;

EID: 84890016628     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0111     Document Type: Article

References (54)

1. Richardson LC, Pollack LA. Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Prac 2005;2:48-53.
2. Giovannucci E, Harlan DM, Archer MC et al. Diabetes and cancer: A consensus report. Diabetes Care 2010;33:1674-1685.
3. Foretz M, Hebrard S, Leclerc J et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the lkb1/ampk pathway via a decrease in hepatic energy state. J Clin Invest 2010;120:2355-2369.
4. Kim YD, Park KG, Lee YS et al. Metformin inhibits hepatic gluconeogenesis through amp-activated protein kinase-dependent regulation of the orphan nuclear receptor shp. Diabetes 2008;57:306-314.
5. Staels B. Metformin and pioglitazone: Effectively treating insulin resistance. Curr Med Res Opin 2006;22 Suppl 2:27-37.
6. Bulcao C, Ribeiro-Filho FF, Sanudo A et al. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Am J Cardiovasc Drugs 2007; 7:219-224.
7. Fidan E, Onder Ersoz H, Yilmaz M et al. The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. Acta Diabetol 2011;48: 297-302.
8. Alimova IN, Liu B, Fan Z et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009;8: 909-915.
9. Zakikhani M, Dowling R, Fantus IG et al. Metformin is an amp kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66: 10269-10273.
10. Ben Sahra I, Regazzetti C, Robert G et al. Metformin, independent of ampk, induces mtor inhibition and cell-cycle arrest through redd1. Cancer Res 2011;71:4366-4372.
11. Isakovic A, Harhaji L, Stevanovic D et al. Dual antiglioma action of metformin: Cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci 2007;64:1290-1302.
12. Liu J, Li M, Song B et al. Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol 2013;31:264-270.
13. Luo Q, Hu D, Hu S et al. In vitro and in vivo antitumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. BMC Cancer 2012;12:517.
14. Soranna D, Scotti L, Zambon A et al. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: A meta-analysis. The Oncologist 2012;17:813-822.
15. Noto H, Goto A, Tsujimoto T et al. Cancer risk in diabetic patients treated with metformin: A systematic review and meta-analysis. PloS One 2012;7: e33411.
16. Mazzone PJ, Rai H, Beukemann M et al. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer 2012;12:410.
17. Tan BX, Yao WX, Ge J et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer 2011;117:5103-5111.
18. Tierney JF, Stewart LA, Ghersi D et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
19. Lin DY, Sullivan PF. Meta-analysis of genome wide association studies with overlapping subjects. Am J Hum Genet 2009;85:862-872.
20. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56:455-463.
21. Nobes JP, Langley SE, Klopper T et al. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int 2012;109:1495-1502.
22. Patel T, Hruby G, Badani K et al. Clinical out comes after radical prostatectomy in diabetic patients treated with metformin. Urology 2010;76: 1240-1244.
23. Jiralerspong S, Palla SL, Giordano SH et al. Met formin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27:3297-3302.
24. Lee DJ, Kim B, Lee JH et al. The effect of met formin on responses to chemotherapy and survival in stage iv colorectal cancer with diabetes. Korean J Gastroenter 2013;60:355-361.
25. Koo YX, Tan DS, Tan IB et al. Effect of concomitant statin, metformin, or aspirin on rituximab treatment for diffuse large b-cell lymphoma. Leuk Lymphoma 2011;52:1509-1516.
26. Kumar S, Meuter A, Thapa P et al. Metformin in take is associated with better survival in ovarian cancer: A case-control study. Cancer 2013;119:555-562.
27. Currie CJ, Poole CD, Jenkins-Jones S et al. Mortality after incident cancer in people with and with out type 2 diabetes: Impact of metformin on survival. Diabetes Care 2012;35:299-304.
28. Kaushik D, Karnes RJ, Eisenberg MS et al. Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol 2013;June 27 [Epub ahead of print].
29. Lega IC, Austin PC, Gruneir A et al. Association between metformin therapy and mortality after breast cancer: A population-based study. Diabetes Care 2013;36:3018-3026.
30. Sadeghi N, Abbruzzese JL, Yeung SC et al. Met formin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012;18:2905-2912.
31. Garrett CR, Hassabo HM, Bhadkamkar NA et al. Survival advantage observed with the use of metformin in patients with type ii diabetes and colorectal cancer. Br J Cancer 2012;106:1374-1378.
32. Romero IL, McCormick A, McEwen KA et al. Relationship of type ii diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol 2012;119:61-67.
33. He X, Esteva FJ, Ensor J et al. Metformin and thia zolidinediones are associated with improved breast cancer-specific survival of diabetic women with her2 breast cancer. Ann Oncol 2012;23:1771-1780.
34. Lee JH, Kim TI, Jeon SM et al. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer 2012;131: 752-759.
35. Bayraktar S, Hernadez-Aya LF, Lei X et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 2012;118:1202-1211.
36. He XX, Tu SM, Lee MH et al. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 2012;22:2640-2645.
37. Chen TM, Lin CC, Huang PT et al. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 2011;26:858-865.
38. Nakai Y, Isayama H, Sasaki T et al. Clinical out comes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: Better prognosis with statin use in diabetic patients. Pancreas 2013;42:202-208.
39. Spratt DE, Zhang C, Zumsteg ZS et al. Metformin and prostate cancer: Reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-716.
40. Hou G, Zhang S, Zhang X et al. Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes. Breast Cancer Res Treat 2013;137:807-816.
41. Spillane SC, Bennett K, Sharp L et al. A cohort study of metformin exposure and survival in pa tients with stage I-III colorectal cancer. Cancer Epidemiol Biomarkers Prev 2013;22:1364-1373.
42. Cossor FI, Adams-Campbell LL, Chlebowski RT et al. Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. Cancer Epidemiol 2013;37:742-749.
43. Sandulache VC, Hamblin JS, Skinner HD et al. Metformin use is associated with improved survival in patients with laryngeal squamous cell carcinoma. Head Neck 2013;June 19 [Epub ahead of print].
44. Zhang F, Yang Y, Skrip L et al. Diabetes mellitus and risk of prostate cancer: An updated meta-analysis based on 12 case-control and 25 cohort studies. Acta Diabetol 2012;49 Suppl 1:235-246.
45. Rubenstrunk A, Hanf R, Hum DW et al. Safety issues and prospects for future generations of ppar modulators. Biochim Biophys Acta 2007;1771: 1065-1081.
46. Tseng SC, Huang YC, Chen HJ et al. Metformin-mediated downregulation of p38 mitogen-activatedproteinkinase-dependentexcision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel. Biochem Pharmacol 2013;85: 583-594.
47. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 2011;71: 3196-3201.
48. Dowling RJ, Zakikhani M, Fantus IG et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007;67:10804-10812.
49. Chen HP, Shieh JJ, Chang CC et al. Metformin decreases hepatocellular carcinoma risk in a dosedependent manner: Population-based and in vitro studies. Gut 2013;62:606-615.
50. Kalender A, Selvaraj A, Kim SY et al. Metformin, independent of ampk, inhibits mtorc1 in a rag gt pase-dependent manner. Cell Metab 2010;11: 390-401.
51. Blandino G, Valerio M, Cioce M et al. Metformin elicits anticancer effects through the sequential modulation of dicer and c-myc. Nature Comm 2012;3:865.
52. Bowker SL, Majumdar SR, Veugelers P et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-258.
53. Terrin N, Schmid CH, Lau J et al. Adjusting for publication bias in the presence of heterogeneity. Stat Med 2003;22:2113-2126.
54. Peters JL, Sutton AJ, Jones DR et al. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med 2007;26:4544-4562.